38 results about "Non antibiotic" patented technology

The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.

The invention discloses trichoderma asperellum TS7-1 capable of efficiently degrading macrolide antibiotics and application of the trichoderma asperellum TS7-1, and belongs to the technical field of microorganisms. The preservation number of the trichoderma asperellum TS7-1 is CGMCC (China General Microbiological Culture Collection Center) No. 41372. The Trichoderma asperellum TS7-1 (CGMCC No.41372) provided by the invention has high-efficiency degradation capability on various macrolide antibiotics (erythromycin, roxithromycin and azithromycin), the removal rates of the Trichoderma asperellum TS7-1, roxithromycin and azithromycin in 36h all reach 85% or above, and the Trichoderma asperellum TS7-1 has high-concentration antibiotic tolerance, degradation rate and degradation spectrum obviously superior to those of other strains in the prior art. The trichoderma asperellum TS7-1 is directly separated from a natural soil body which is not polluted by antibiotics, has no animal and plant pathogenicity hidden danger, has no microbial toxicity to degradation products of macrolide antibiotics, avoids secondary pollution, and has excellent environmental safety.

The invention belongs to the technical field of biological medicines, and particularly discloses application of (E)-BCI hydrochloride in preparation of a medicine for treating sepsis. According to the application of the (E)-BCI hydrochloride in preparation of the medicine for treating sepsis, by inhibiting the activity of bispecific phosphatase 6, a mitogen activated protein kinase signal channel is regulated and controlled, and the expression level of inflammatory factors IL-1beta and TNF-alpha is reduced. The invention discloses application of (E)-BCI hydrochloride in preparation of drugs for treating sepsis, BCI enters from a new target for regulating inflammation and immune balance through a targeted DUSP6 / MAPK signal channel, a non-antibiotic-dependent drug is provided for treatment of sepsis, and the (E)-BCI hydrochloride is especially suitable for systemic inflammatory response syndromes caused by infection, operations, wounds and other inducements, and has a wide application prospect. Wide clinical application prospects are realized.

A veterinary composition comprising a therapeutically effective amount of a zeolite and at least one member of the Lactobacilli genus, and at least one veterinary acceptable excipient is provided. The

The present invention discloses an antibacterial artificial nanocell and its preparation method and application. The antibacterial artificial nanocell is used for preparing a drug for treating osteomyelitis, and the antibacterial artificial nanocell is prepared through the following steps: mixing polyvinylpyrrolidone or its aqueous solution, CuCl2·2H2O or its aqueous solution, FeCl2·4H2O or its aqueous solution, elesclomol or its DMSO solution, NaOH or its aqueous solution, and H2O2 or its aqueous solution, stirring evenly, washing, ultrafiltering, and centrifuging to obtain nanoparticles; preparing cell membranes by using bone marrow stromal stem cells; mixing the nanoparticles and the cell membranes evenly, and incubating and extruding them by ultrasound to obtain the antibacterial artificial nanocell; wherein, the mass ratio of the protein of the nanoparticles to the cell membranes is 1:(0.9-1.1). The antibacterial artificial nanocell provided by the present invention effectively avoids the two major clinical problems of large side effects caused by long-term and high-dose use of antibiotics and high risk of debridement surgery in the traditional treatment of osteomyelitis, and kills bacteria from the perspectives of mediating Fenton reaction and cuproptosis, two non-antibiotic principles, so as to achieve excellent osteomyelitis treatment effect.

The invention provides an alcohol extraction method of cortex phellodendri and application of the cortex phellodendri alcohol extract as a liniment.The invention relates to the technical field of medicine.The alcohol extraction method of cortex phellodendri is provided, the alcohol extract of cortex phellodendri is obtained through the extraction method, the bacteriostatic activity of the alcohol extract of cortex phellodendri on propionibacterium acnes is 1.56 mg / mL, and the bacteriostatic activity of the alcohol extract of cortex phellodendri is remarkably superior to that of other existing traditional Chinese medicine extraction bacteriostatic schemes; meanwhile, the invention provides the golden cypress alcohol extract liniment for inhibiting acnes, propionibacterium acnes are synergistically inhibited by reducing the protein expression levels of Src, Akt and mTOR in skin tissues and destroying the completeness of cell walls and cell membranes of the propionibacterium acnes, and the liniment is not added with a penetration enhancer, does not irritate the skin, is safer to use, and has a good application prospect. The formed medicine film reduces evaporation of moisture on the skin surface, the medicine is promoted to be slowly released through cuticle, an animal model verifies that acnes rapidly fade after 4 days, a non-antibiotic treatment scheme is provided for light and moderate acnes, and a better treatment effect is achieved.

The invention discloses a Ti < 3 > C < 2 > T < x > MXene-GQD nano composite material as well as a preparation method and application thereof, and relates to the technical field of composite material preparation. The method comprises the following steps: dissolving LiF in a hydrochloric acid solution, and adding Ti3AlC2 powder to prepare a colloidal solution; the preparation method comprises the following steps: dissolving citric acid in deionized water, and then carrying out hydrothermal carbonization to prepare a GQD solution; and mixing the colloidal solution and the GQD solution, and stirring to obtain the nano composite material. According to the invention, the Ti3C2Tx MXene two-dimensional lamellar structure is utilized to stabilize the GQD nanoparticles, so that the GQD nanoparticles are uniformly dispersed and are not easy to agglomerate, and the long-term uniformity is ensured; by utilizing the photothermal effect of Ti3C2Tx MXene and the photodynamic effect of GQD, the dual photoresponse antibacterial efficiency is realized, the infection of drug-resistant bacteria can be efficiently inhibited, a non-antibiotic way is provided for treating the drug-resistant bacteria, and the infection problem and the related postoperative pain problem are effectively controlled in practice.

The present invention relates to a strain of filamentous fungus belonging to the Ascomycetes division, excluding fungi belonging to the Saccharomycetes class, in which a gene encoding an arginine permease (CAN1), or a variant or orthologous gene, has been inactivated. The invention also relates to the various uses of this strain, as well as the genetic modification process for obtaining a strain according to the invention. The invention further relates to the use of L-canavanine as a selection marker for transformants in which a gene encoding an arginine permease (CAN1), or a variant or orthologous gene, has been inactivated. (no figure)

The application belongs to the technical field of non-antibiotic compounds as bacteriostatic agents, and discloses an application of a known non-antibiotic compound, cladrabine, in inhibiting the growth of multi-drug resistant Klebsiella pneumoniae. The application finds that cladrabine can inhibit the growth of multi-drug resistant Klebsiella pneumoniae, and the minimum bacteriostatic concentration reaches 64 mg / L. Further exploration of the bacteriostatic mechanism finds that after exposure to cladrabine, the permeability of the bacterial cell membrane is enhanced, and the macromolecular substances (nucleic acids and proteins) in the cell are excreted, causing the integrity of the bacterial cell membrane to be destroyed, and further causing the death of Klebsiella pneumoniae. The application proposes that cladrabine can destroy the cell membrane of bacteria, change the permeability of the cell membrane, has a good inhibitory effect on multi-drug resistant Klebsiella pneumoniae, and can be further applied to the preparation of related drugs.

The application discloses a wound dressing and a preparation method and application thereof; the wound dressing comprises polymer flexible fibers and cobalt-iron layered double hydroxide nanosheets dispersed in the polymer flexible fibers; the cobalt-iron layered double hydroxide nanosheets contain a cobalt vacancy structure in a crystal lattice. The wound dressing has a strong "electron capture effect" due to the cobalt vacancy. The wound dressing can physically capture electrons on a respiratory transmission chain of a pathogenic bacterial cell membrane, interferes with transmembrane proton transfer and ATP synthesis, directly kills the bacteria through "metabolic starvation", and further has a broad-spectrum physical bactericidal function independent of antibiotics. The wound dressing has excellent superoxide dismutase-like and catalase-like activities, can long-acting capture and remove active oxygen such as superoxide anions and hydrogen peroxide in an inflammatory microenvironment of a wound, promotes macrophages to polarize to a M2 phenotype for promoting repair, and has anti-inflammatory and pro-angiogenic functions.

The present invention discloses a fully human SEB monoclonal antibody against Staphylococcus aureus enterotoxin B and its applications. The amino acid sequences of CDR1, CDR2, and CDR3 in the variable region of the heavy chain of the antibody are shown as SEQ ID NO.5, SEQ ID NO.6, and SEQ ID NO.7 respectively; the amino acid sequences of CDR1, CDR2, and CDR3 in the variable region of the light chain are shown as SEQ ID NO.9, SEQ ID NO.10, and SEQ ID NO.11 respectively; the antibody can specifically bind to Staphylococcus aureus enterotoxin B and can be used for the treatment, prevention, or diagnosis of Staphylococcus aureus infections and toxic shock syndrome caused by enterotoxin B, which will become an important direction in the research field of "non-antibiotic" treatment of drug-resistant Staphylococcus aureus infections and control of the development of drug resistance.

The invention relates to the field of biological medicine and immunology, in particular to preparation and application of an anti-staphylococcus aureus enterotoxin B antibody. A heavy chain variable region of the antibody SEB-A8 provided by the invention comprises CDR sequences as shown in SEQ ID NO: 1-3, a light chain variable region of the antibody SEB-A8 comprises CDR sequences as shown in SEQ ID NO: 9-11, and the antibody SEB-A8 has important application value in treatment, prevention or diagnosis of staphylococcus aureus infection. Experimental data show that the antibody can effectively neutralize the superantigen activity of SEB and significantly improve the survival rate of MRSA infected mice, has a dose-dependent protection effect, can be used as a non-antibiotic treatment strategy, is used for treatment of methicillin-resistant staphylococcus aureus infection, has great significance in controlling development of bacterial drug resistance, and has a broad application prospect. And a new research direction is provided for clinical anti-infection treatment.

The invention provides a preparation method of a high-temperature-resistant antibacterial sputum suction catheter, and belongs to the technical field of medical instruments. The preparation method comprises the following steps: quaternary ammonium salt chitosan is treated by chitosanase to obtain modified chitosan, polytetrahydrofuran, polyethylene glycol and diisocyanate react to obtain a prepolymer, the prepolymer, dimethylolpropionic acid and the modified chitosan react to obtain a polyurethane prepolymer, modified silane and the polyurethane prepolymer are mixed to obtain a mixed material, and the mixed material is dried to obtain a finished product. And performing extrusion molding on the mixture to obtain the high-temperature-resistant antibacterial sputum suction catheter. Hydrophilic groups in the modified silane and polyurethane polymer can reduce the friction force on the surface of the sputum suction catheter and reduce vascular endothelial injury; in addition, quaternary ammonium salt structures in the resveratrol and the modified chitosan can jointly destroy metabolism of bacteria to achieve a good antibacterial effect, and the combined non-antibiotic antibacterial strategy can delay generation of drug-resistant bacteria.

The invention discloses an application of a phthalocyanine compound and a delivery system thereof in preparation of an anti-clostridium difficile toxin drug, and discovers that phthalocyanine can specifically target TFPI, CSPG4 and FZD1, 2, 7 receptor binding domains of clostridium difficile toxin B (TcdB), and effectively inhibits binding of toxin and host cells. In-vitro experiments prove that the phthalocyanine (Phthalocyanine, Pc) can be used for remarkably relieving the cytopathy induced by TcdB and has no cytotoxicity. In order to improve the curative effect, an extracellular vesicle (S-EV) from saccharomyces boulardii is creatively adopted to construct a drug loading system S-EV-Pc, and the pH responsive intestinal targeted delivery of the drug is realized. Animal experiments show that the preparation can significantly improve the survival rate of infected gerbil to 100%, significantly improve diarrhea symptoms, reduce intestinal TcdB load and relieve tissue pathological damage. The invention discloses the potential of phthalocyanine as a non-antibiotic small molecule drug in treatment of clostridium difficile infection (CDI) for the first time, and provides a brand new strategy and an experimental basis for developing a novel anti-CDI preparation.

The present invention relates to a non-antibiotic antimicrobial composition, new uses and methods of medical treatment or prophylaxis. In particular, the present invention relates to a non-antibiotic antimicrobial composition comprising a zeolite and at least one member of the Lactobacilli genus for the treatment of a disease or a condition associated with or caused by Helicobacter spp such as Helicobacter pylori.

The invention relates to a preparation method and application of an angstrom silver antibacterial hydrogel. The invention belongs to the technical field of antibacterial materials, and discloses a modified starch coated silver ion slow-release gel composition which is prepared from easily available raw materials including a silver ion source, powder grafted acrylic acid, alpha-potato starch and the like. The composition can be used in non-antibiotic nursing drugs or disinfection products on the skin surface. The composition can keep the color characteristic for a long time after being refrigerated, and can keep the gel characteristic for a long time below 20 DEG C. Meanwhile, expanded production is easy, and related application requirements are met.

The subject invention provides a novel class of mixed-metal chalcogenide compounds exhibiting POD-like catalytic activity, efficient photothermal conversion under NIR irradiation, and broad-spectrum antimicrobial properties. The invention further provides hydrogel formulations incorporating these compounds in a polymeric matrix, as well as their use in a range of biomedical applications, such as treating infected wounds, preventing surgical site infections, and delivering localized, non-antibiotic antimicrobial therapy.

The application belongs to the technical field of biological medicine, and particularly relates to application of (E)-BCI hydrochloride in preparation of a medicine for treating sepsis. The application provides application of (E)-BCI hydrochloride in preparation of the medicine for treating sepsis. (E)-BCI hydrochloride regulates a DRD1 gene through targeting, quiets an interferon stimulation storm, reduces abnormal activation of astrocytes, reduces a level of an inflammatory factor, improves expression of a nerve activity gene, and provides a non-antibiotic dependent medicine for sepsis treatment from a new target point of regulating inflammation and immune balance, and is particularly suitable for systemic inflammatory response syndrome caused by various causes such as infection, operation and trauma, and has a wide clinical application prospect.

The invention discloses an antibacterial and anti-inflammatory preparation with tackifying and moisturizing effects. The preparation at least contains an antibacterial component, a non-antibiotic anti-inflammatory component and a tackifying and moisturizing component, wherein the antibacterial component is a component containing effective iodine; the non-antibiotic anti-inflammatory component is one or a combination of glycyrrhizic acid compounds; the tackifying and moisturizing component comprises one or a combination of more of glycerol and cellulose substances. When the preparation is used, the tackifying and moisturizing component can increase the adhesive force of the preparation and reduce the loss speed of water in the preparation, so that the purposes of tackifying and moisturizing are achieved, and the acting time of the preparation acting on a treatment part is effectively prolonged; the effective iodine can play a bactericidal role, meanwhile, the glycyrrhizic acid compounds play a continuous anti-inflammatory role to prevent inflammation expansion and shorten the duration time of inflammation, and compared with an original treatment technology, the preparation can improve the treatment efficiency of infected wounds.

The present invention discloses a fully human Hla monoclonal antibody against Staphylococcus aureus α-hemolysin and its application. The amino acid sequences of the variable regions CDR1, CDR2, and CDR3 of the antibody heavy chain are shown as SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3; the amino acid sequences of the CDR1, CDR2, and CDR3 of the light chain variable region are shown as SEQ ID NO.4, SNN, and SEQ ID NO.6. The antibody can specifically bind to Staphylococcus aureus α-hemolysin or free α-hemolysin, and can be used for treating, preventing, or diagnosing Staphylococcus aureus infections, etc., and will become an important research direction in the field of "non-antibiotic" treatment of methicillin-resistant Staphylococcus aureus infections and controlling the development of drug resistance.

This invention relates to the fields of biomedicine and immunology, and particularly to the preparation and application of an anti-Staphylococcal enterotoxin B antibody. The antibody provided by this invention has a SEB-A8 heavy chain variable region containing CDR sequences as shown in SEQ ID NO:1-3, and a light chain variable region containing CDR sequences as shown in SEQ ID NO:9-11. It has significant application value in the treatment, prevention, and diagnosis of Staphylococcus aureus infections. Experimental data show that this antibody can effectively neutralize the superantigen activity of SEB, significantly improve the survival rate of MRSA-infected mice, and exhibit a dose-dependent protective effect. It can be used as a "non-antibiotic" treatment strategy for the treatment of methicillin-resistant Staphylococcus aureus infections, which is of great significance in controlling the development of bacterial resistance and provides a new research direction for clinical anti-infective therapy.

The invention provides a high-temperature-resistant antibacterial sputum suction catheter and a preparation method thereof, and belongs to the technical field of medical instruments. The preparation method comprises the following steps: quaternary ammonium salt chitosan is treated by chitosanase to obtain modified chitosan, polytetrahydrofuran, polyethylene glycol and diisocyanate react to obtain a prepolymer, the prepolymer, dimethylolpropionic acid and the modified chitosan react to obtain a polyurethane prepolymer, modified silane and the polyurethane prepolymer are mixed to obtain a mixed material, and the mixed material is dried to obtain a finished product. And performing extrusion molding on the mixture to obtain the high-temperature-resistant antibacterial sputum suction catheter. Hydrophilic groups in the modified silane and polyurethane polymer can reduce the friction force on the surface of the sputum suction catheter and reduce vascular endothelial injury; in addition, quaternary ammonium salt structures in the resveratrol and the modified chitosan can jointly destroy metabolism of bacteria to achieve a good antibacterial effect, and the combined non-antibiotic antibacterial strategy can delay generation of drug-resistant bacteria.

The present invention provides an application of an antibacterial compound in inhibiting Vibrio, an antibacterial and washing composition, and relates to the technical field of antibacterial compounds. The compound used to inhibit Vibrio of the present invention is of natural origin, non-antibiotic, and has a very effective inhibitory effect on Vibrio. The Vibrio-inhibiting composition provided by the present invention contains 0.005% to 0.1% of the above-mentioned antibacterial compound and 0.005% to 0.5% of citrate. The antibacterial effect of the antibacterial compound is further enhanced by citrate, filling the technical gap in fruit and vegetable dishwashing detergents and hand cleansers in inhibiting the growth of Vibrio.

An apparatus is provided for a removable catheter visible light therapy system designed to deliver a non-antibiotic in vivo bactericidal treatment agent. A medical device assembly is provided for removably insertion into a catheter (36) having a lumen (30). The medical device assembly includes an electromagnetic radiation (EMR) source (26) for providing non-ultraviolet therapeutic EMR of sufficient intensity to inactivate one or more infectious agents and / or stimulate the growth of healthy cells to produce a healing effect, and a removable EMR conduction system (18) at least partially insertable into and removable from the lumen of the catheter. The EMR conduction system includes at least one optical element (14) that propagates the therapeutic EMR axially through an insertable elongate body (24). The elongate body can have an outer surface between the coupling end and the distal end (34) with at least one modification that allows the therapeutic EMR to radiate radially from the elongate body adjacent the modification. Such modification can be tapered along the outer surface.

The application discloses a preparation method of a nano-mineral composite enzyme against drug-resistant bacteria, and belongs to the technical field of antibacterial materials and functional nanomaterials. The steps comprise the following: mixing vanadium-manganese nano-enzyme precursor powder prepared by taking ammonium metavanadate and a manganese source as raw materials with natural montmorillonite to prepare in-situ loaded composite precursor powder, and then calcining the composite precursor powder to obtain the nano-mineral composite enzyme against drug-resistant bacteria. The two-dimensional layered structure of the montmorillonite is used to anchor the active components of vanadium and manganese, so that the highly dispersed active sites and multi-enzyme synergistic catalysis are realized, and the generation rate of active oxygen is significantly improved. The obtained composite enzyme has high killing capacity for drug-resistant bacteria and good biocompatibility, and can be used for preparing biomedical antibacterial materials, antibacterial materials against drug-resistant bacterial infection or non-antibiotic antibacterial materials.

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and / or treatment of bacterial infections and antibacterial-induced dysfunctions. The compositions of the present invention demonstrate high species-specificity in inhibiting the growth of a small number of bacterial species, and most importantly are effective also against multi drug resistant (MDR) clinical isolate species. Interestingly, one of those combinations pairs a non-antibiotic drug, vanillin, with an antibiotic drug, spectinomycin, to demonstrate a surprisingly strong inhibitory effect on the growth of clinically relevant Gram-negative pathogenic and multi-drug resistant E. coli isolates. A second set of compounds combines the polymyxin colistin with loperamide, a rifamycin, or a macrolide. Importantly, this invention relates to combinations that enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development efforts in order to prevent major side effects of antibacterial strategies. This invention also relates to pharmaceutical combinations useful to prevent an adverse effect on the gut microbiome, induced by the use of antibacterial compounds.

The application discloses a strain of macrolide antibiotic high-efficiency degradation fungus Trichoderma asperellum TS7-1 and application thereof, and belongs to the technical field of microorganisms. The preservation number of the Trichoderma asperellum TS7-1 is CGMCC No.41372. The strain Trichoderma asperellum TS7-1 (CGMCC No.41372) provided by the application has high-efficiency degradation capacity for various macrolide antibiotics (erythromycin, roxithromycin and azithromycin), and the removal rates of the three antibiotics are all above 85% within 36 hours. The high-concentration antibiotic tolerance, degradation rate and degradation spectrum of the Trichoderma asperellum TS7-1 are obviously superior to those of other strains in the prior art. The Trichoderma asperellum TS7-1 is directly separated from a natural soil body without antibiotic pollution, has no hidden danger of animal and plant pathogenicity, and has no microbial toxicity to degradation products of the macrolide antibiotics, so that secondary pollution is avoided, and excellent environmental safety is achieved.

The invention discloses a non-antibiotic small-molecule inhibitor of clostridium difficile toxin B and a screening method of the non-antibiotic small-molecule inhibitor. According to the method, a plurality of broad-spectrum small-molecule inhibitors targeting all TcdB receptor binding interfaces at the same time are found through virtual screening and a multi-stage calculation strategy, and the inhibition effect of the broad-spectrum small-molecule inhibitors is verified by combining cell experiments; a lead compound and an action mechanism theoretical support are provided for development of non-antibiotic anti-CDI drugs, and a screening strategy and a screening result can also provide a theoretical basis and an experimental basis for development of a next-generation precise anti-CDI therapy.

This invention discloses a fully human monoclonal antibody Hm0699 against Staphylococcus aureus α-hemolysin and its applications. The antibody comprises a heavy chain and a light chain. The amino acid sequences of the variable regions CDR1, CDR2, and CDR3 of the heavy chain are shown in SEQ ID NO. 5, SEQ ID NO. 6, and SEQ ID NO. 7; the amino acid sequences of the variable regions CDR1, CDR2, and CDR3 of the light chain are shown in SEQ ID NO. 8, SEQ ID NO. 9, and SEQ ID NO. 10. This antibody can specifically bind to Staphylococcus aureus α-hemolysin and can be used for the treatment, prevention, or diagnosis of Staphylococcus aureus infections. It represents an important direction in the research field of "non-antibiotic" treatment of methicillin-resistant Staphylococcus aureus infections and control of drug resistance development.

The present invention discloses a Cu2O-BSO antibacterial nanoparticle, a preparation method thereof and an application. The preparation method comprises the following steps: (1) preparing Cu2O nanoparticles by a Cu(NO3)2 reduction method; (2) loading buthionine sulfoximine wrapped with dopamine on the Cu2O nanoparticles obtained in step (1); (3) incubating with polyethylene glycol in the product obtained in step (2) to obtain the Cu2O-BSO antibacterial nanoparticle. The nanoparticles of the present invention can effectively release Cu2O and BSO, and the two synergistically produce an effect of inducing cuproptosis in bacteria and inhibiting quorum sensing, which can affect the formation of biofilms and the expression of virulence factors. This non-antibiotic synergistic antibacterial effect is not easily resisted by drug-resistant bacteria, so it can effectively inhibit drug-resistant pathogens and can be used to treat diseases caused by drug-resistant bacterial infections.